Teva, along with other global drug companies, is accused of conspiring to inflate the prices of their generic therapies by as much as 1,000 percent, according to the lawsuit filed last Friday. The allegations include drug companies and their executives were not only involved in a price-fixing scheme, but were aware their alleged actions were illegal.
Company executives avoided any written records of interactions by arranging meetings at industry meals, parties, rounds of golf, and networking events, according to The New York Times. Other companies named in the report include Pfizer Inc. (NYSE: PFE), Novartis AG (NYSE: NVS) and Mylan NVM (NASDAQ: MYL).
Teva's stock was the clear underperformer among the group as the Israel-based company was singled out by NYT for raising prices on nearly 400 formulations of 112 generic drugs.
Companies Deny Wrongdoing
Teva said in a statement it has "not engaged in any conduct that would lead to civil or criminal liability." The company also said it "continues to review the issue internally."
“We believe that these claims are without merit and will vigorously contest them,” Novartis said.
Pfizer said its subsidiary in charge of generic drugs intends to "vigorously defend" the allegations.
Credit Suisse Stays Sidelined On Teva: 'Our Growth Expectations Are Below That Of The Company'
Mylan's Disappointing Outlook Rattles Analysts, Investors
See more from Benzinga
- 2 Analysts Turn Incrementally Bullish On IAC InterActive
- Yelp Shares Tank After Q1 Print: 2 Analyst Takes
- Analyst Says Dogfish Head 'Could Be Trophy Material' For Boston Beer
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.